Nureca Limited (NURECA) Fair Value & Analysis
Healthcare · IN · Market cap ₹2.3B
Fair value as of: Jul 3, 2026
From 25 valuation models · updated today
Share price −2.5% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹211.26 – ₹339.88 · fair‑value band ₹70.96 – ₹104.05 · the ₹233.96 price screens above the ₹104.05 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Nureca Limited (NURECA) currently trades at ₹233.96, while our model-based Fair Value estimate is ₹104.05 — implying the stock looks roughly 55.5% overvalued today. We read business quality at 57/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Nureca Limited generated revenue of ₹1.5B at a net margin of 1.4%. Revenue grew 11.5% year over year. It earns a return on equity of 1.1%. The balance sheet holds a net cash position of ₹392M. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Nureca Limited provides home healthcare and wellness products in India. The company offers chronic disease products, such as nebulizers, blood pressure monitors, finger pulse oximeters, glucose meters, and thermometers, as well as connected products; orthopedic products, including massagers, pain management products, posture correctors, and rehabilitation products; and humidifiers and steamers, personal scales, yoga and exercise products, fitness tracking products, and dental and personal care products. It also provides mother and baby care products comprising baby feeding products, carry cots, baby skincare products, and bottle warmers and steamers; nutritional supplements and weight management products; and ECG products, fitness trackers, and smart weighing scales. In addition, the company provides orthopedic cushions, heating pads, and breast pumps. The company offers its products under the Dr Trust, Dr Physio, and Trumom brands. It markets its products through e-commerce …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Nureca Limited reported revenue of ₹1.5B in FY2026 versus ₹2.6B in FY2022, a compound −12.9%/yr. Reported net income was ₹20.8M in FY2026, compounding −53.6%/yr from FY2022.
Is NURECA fairly valued? → Check now
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABTT34 | R$39.41 | R$30.42 | -23% |
| Stryker Corporation S1YK34 | R$79.21 | R$43.74 | -45% |
| Medtronic plc MDT | $81.67 | $60.02 | -27% |
| Boston Scientific Corporation B1SX34 | R$229.30 | R$43.33 | -81% |
| Edwards Lifesciences Corporation EW | $85.98 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €35.10 | €26.55 | -24% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Nureca Limited (NURECA) undervalued?
What is the fair value of NURECA?
What is the quality score of NURECA?
What is the revenue of Nureca Limited (NURECA)?
What is the net profit margin of NURECA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.